Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Maybe try reading the news release? Right your one of those

<< Previous

Bullboard Posts

Next >>

Comment by Bvukmanicon Jan 15, 2021 9:52pm

264 Views

Post# 32312311

RE:Maybe try reading the news release? Right your one of those

This news was in an md&a released over 3 months ago. It doesn't mention the license fee to Salzman is $1.2 million cash (and 130 million shares).

Of course the company would need to consolidate to raise capital, assuming they're able to raise capital. I doubt anyone would want to finance a pre-clinical covid therapeutic at this point when vaccines are available. Didn't Salzman apply to BARDA in July, before they lost their contract for CILI? Obviously BARDA isn't interested at this point. Development costed at $20 million. Keep dreaming!

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market